Browse

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

DC Field Value Language
dc.contributor.authorPark, Sehhoon-
dc.contributor.authorKeam, Bhumsuk-
dc.contributor.authorKim, Se Hyun-
dc.contributor.authorKim, Ki Hwan-
dc.contributor.authorKim, Yu Jung-
dc.contributor.authorKim, Jin-Soo-
dc.contributor.authorKim, Tae Min-
dc.contributor.authorLee, Se-Hoon-
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorLee, Jong Seok-
dc.contributor.authorHeo, Dae Seog-
dc.date.accessioned2020-04-27T11:19:20Z-
dc.date.available2020-04-27T11:19:20Z-
dc.date.issued2015-10-
dc.identifier.citationCancer Research and Treatment, Vol.47 No.4, pp.630-637-
dc.identifier.issn1598-2998-
dc.identifier.other65724-
dc.identifier.urihttps://hdl.handle.net/10371/165356-
dc.description.abstractPurpose Platinum-based doublet chemotherapy is the treatment of choice for patients with non-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet as second-line therapy after failure of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for NSCLC patients has not yet been elucidated. The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. Materials and Methods We designed a multicenter retrospective cohort study of 314 NSCLC patients with EGER mutations who received an FGFR TKI as first-line palliative chemotherapy. Our analysis included 83 patients who failed EGFR TKI therapy and received second-line cytotoxic chemotherapy. Results Forty-six patients were treated using a platinum-based doublet and 37 patients were treated usi ng singlet pemetrexed. The overall response rates of patients receiving a platinum-based doublet and patients receiving pemetrexed were17.4% and 32,4%, respectively (p=0.111). The median progression-free survival (PFS) of patients receiving pemetrexed was significantly longer than that of patients receiving a platinum-based doublet (4.2 months vs. 2.7 months, respectively; p=0.008). The hazard ratio was 0.54 (95% confidence interval, 0.34 to 0.86; p=0.009). Conclusion Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGER mutations who failed first-line EGFR TKI. Conduct of prospective studies for confirmation of our results is warranted.-
dc.subjectPlatinum-
dc.subjectPemetrexed-
dc.subjectNon-small-cell lung carcinoma-
dc.subjectEpidermal growth factor receptor-
dc.titlePemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations-
dc.typeArticle-
dc.contributor.AlternativeAuthor김동완-
dc.contributor.AlternativeAuthor이종석-
dc.contributor.AlternativeAuthor허대석-
dc.identifier.doi10.4143/crt.2014.244-
dc.citation.journaltitleCancer Research and Treatment-
dc.identifier.scopusid2-s2.0-84946735975-
dc.citation.endpage637-
dc.citation.number4-
dc.citation.startpage630-
dc.citation.volume47-
dc.identifier.urlhttps://www.e-crt.org/journal/view.php?doi=10.4143/crt.2014.244-
dc.identifier.rimsid65724-
dc.identifier.sci000362895800011-
dc.identifier.kciidART002039745-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse